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Reply
We appreciate the interest of Drs. Mehta and Singla in our paper
and the opportunity to respond to the excellent points they raise.
We agree that body mass index (BMI) is an imperfect measure of
adiposity and that other measures of adiposity, such as waist
circumference and body composition analysis, may offer benefits in
understanding the cardiovascular pathophysiology associated with
obesity. At the population level, this distinction may be less
clinically relevant because different measures of adiposity perform
similarly (1). BMI, although imperfect, offers some practical
advantages over other measurements. It is easily understood, is
typically captured as part of routine clinical care by personnel
without specific training and at no added cost, and has been the
most commonly reported measure of obesity, therefore facilitating
comparisons with the existing literature. Numerous studies have
documented an association between increased BMI and incident
cardiovascular disease and death (2,3). In the population of
patients with clinical cardiovascular disease, a high BMI is very
likely to indicate an obese patient. The point made by Drs. Mehta
and Singla that a low BMI is a poorer proxy for the absence of
adiposity in nonobese patients is well taken.
Regarding the implications of the paradoxical increase in risk
that we observed in individuals with a normal BMI that disap-
peared with multivariable adjustment (4), we believe that this is
similar to the signal of increased risk that has previously been seen
among underweight individuals in previous studies (5). Because
obesity predisposes to the development of cardiovascular risk
factors and to incident cardiovascular disease, the ST-segment
elevation myocardial infarction (STEMI) population is more obese
than the general population. It is now uncommon for a normal
weight person to present with STEMI. Our admittedly speculative
comment is simply that those patients with myocardial infarction
(MI) despite normal weight may be hiding occult malefic factors
and that these unrecognized factors may in part drive the pooreroutcomes seen in normal weight versus overweight and mildly
obese patients after MI.
We also concur with their comment that the higher in-hospital
mortality seen in the most obese patients likely represents either an
intrinsic adverse effect of extreme obesity or a deleterious influence
of extreme obesity on treatment patterns or efficacy. We were
reassured to see that the process of care measures were quite similar
for even the most obese patients, which argues against a deleterious
impact of extreme obesity on treatment patterns. We agree that it
is possible that extremely obese patients may have qualitatively or
quantitatively different pathophysiological contributors to risk
compared with less obese individuals and that medication dosing
may be inadequate in the very obese. Clearly, more investigation is
needed in extremely obese individuals to identify the most appro-
priate strategies for treating this rapidly growing segment of the
population.
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